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INTRODUCTION 
Human Immunodeficiency Virus Type 1 (HIV) has
pervaded New York City since the early days of the
epidemic (see Figure 1). The peak of reported Acquired
Immunodeficiency Syndrome cases occurred in the
early 1990s; however, according to the NYC Depart-
ment of Health and Mental Hygiene (NYC DHMH,
2005), the number of persons living with HIV/AIDS is
steadily increasing because patients are living longer
lives on combination therapy. HIV, therefore, remains
a significant health concern for New Yorkers, especially
since it is concentrated in the poorest neighborhoods,
including the South Bronx.
Despite the fact that most individuals have a basic
understanding of the modes of transmission of HIV,
over 4,000 new cases were reported in 2003 in NYC,
bringing the total to greater than 92,000 people living
with HIV/AIDS throughout the city (NYC DHMH, 2005).
Eighty-one percent of the newly diagnosed cases were
in blacks and Hispanics. HIV is highly prevalent in the
Bronx; it is present in 1.5% of the Bronx population. In
fact, out of the five boroughs of NYC, the rate of new
HIV diagnoses is highest in the Bronx (78.2 per 100,000)
(NYC DHMH, 2005). For those who knew the mode of
transmission by which they acquired the virus, approxi-
mately 10% contracted HIV from injection drug use.
The majority of cases of HIV are sexually transmitted
(63.5% in men; 40% in women) and perinatal transmis-
sion now only accounts for less than one percent of
new cases of HIV (NYC DHMH, 2005). These statistics
indicate that risky behaviors are still occurring to a
large extent throughout NYC and are responsible for
the majority of new cases of HIV.
This review provides a historical perspective on
research performed at both the Albert Einstein College
of Medicine (AECOM) and the Montefiore Medical
Center (MMC). It discusses how the Center for AIDS
Research (CFAR) has been an invaluable resource for
the network of investigators at AECOM/MMC and it
surveys the past and current HIV-related research proj-
ects in the Bronx and beyond.
HIV RESEARCH AT THE ALBERT EINSTEIN COLLEGE OF
MEDICINE: THE EARLY YEARS
During the 1980s, the investigators of AECOM and
MMC were on the front lines of the fight against HIV in
terms of both research and patient care because the
high rate of substance abuse in the Bronx facilitates HIV
spread. Researchers sought to characterize the natural
history of HIV infection and its modes of transmission.
For example, Drs. Robert Klein and Ellie Schoenbaum
searched for links with drug abuse and homosexuality
(Moll et al., 1982; Small et al., 1983), while Dr. Arye
Rubinstein described pediatric HIV/AIDS and compared
it to adult forms (see Rubinstein, 1989 for review).
Research at AECOM/MMC was also crucial in improving
the understanding behind mother-to-child transmission
of HIV (Kollmann et al., 1991; Soeiro et al., 1992) and
the nature of opportunistic infections, such as tubercu-
losis and oral candidiasis (Klein et al., 1984; Selwyn,
1991). In 1985, researchers at the AECOM/MMC estab-
lished a cohort called the HIV Epidemiological Research
on Outcomes and they worked in collaboration with
investigators who organized the Montefiore Substance
Abuse Treatment Program. These programs provided
large numbers of HIV-infected and substance abuse
patients for clinical study.
The pioneering research that began at AECOM/MMC
and the successful recruitment of HIV-infected patients
in the Bronx into several clinical trials led to the initial
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funding of the AECOM/MMC Center for AIDS Research
(CFAR) by the National Institutes of Health (NIH) in
1988. The CFAR was spearheaded by Dr. Rubinstein, a
prominent pediatrician. The AECOM/MMC CFAR was
highly successful. It focused on clinical research, and
expanded to foster relationships with the Mount Sinai
Medical Center, Beth Israel Medical Center, and St.
Luke’s-Roosevelt Hospital Center. In parallel with
continuing to characterize the natural history of HIV,
investigation focused on the development and evalua-
tion of new treatments, such as reverse transcriptase
inhibitors and protease inhibitors, as they became
widely available in the US and in NYC. The high preva-
lence of HIV infection in the Bronx provided
AECOM/MMC physicians with ample research subjects,
while CFAR investigators continued with their strong
research programs. NIH funding for the multi-institu-
tional CFAR continued through 1998. 
As the main modes of transmission became defined and
the etiological cause of AIDS was identified and char-
acterized, the focus of national research shifted
towards ways to control the infection in individuals
and impede its spread in populations. Several reasons
contributed to the unsuccessful applications to the NIH
for refunding the CFAR, including its heavy emphasis
on clinical research, and the complex logistical issues
related to the overwhelmingly large structure of the
multi-institutional CFAR. Therefore, the AECOM/MMC
CFAR was revamped to focus solely on AECOM/MMC
investigators and to concentrate on a translational
approach, linking clinical and basic science research
under the leadership of Dr. Harris Goldstein, who previ-
ously served as the Director of the SCID-hu mouse core.
The CFAR was funded by the NIH in 2003 and was inau-
gurated with a ceremony at which one of the world’s
leading AIDS investigators, Dr. Anthony Fauci, Director
of the National Institute of Allergy and Infectious
Diseases (and Dr. Goldstein’s former mentor) gave the
invited lecture. 
MAKING CHANGES FOR THE FUTURE: THE CENTER FOR
AIDS RESEARCH IS REDESIGNED
With the new leadership of the AECOM/MMC CFAR
came a reorganization of its structure. The current
CFAR is divided into cores with specific purposes (see
FIGURE 1: The effect of the HIV epidemic in New York and clinical milestones in the field of HIV medicine. This figure is reprinted
with the permission of the New York City Department of Health Mental Hygiene (New York City Department of Health Mental 
Hygiene, 2005).
CORE
TABLE 1:  THE STRUCTURE AND FUNCTIONS OF THE CORE FACILITIES OF THE AECOM/MMC CFAR
Administrative
 Director: Harris Goldstein 
 Co-Director: William Jacobs, Jr. 
• To provide guidance for the AECOM/MMC CFAR
• To oversee the functioning of individual cores
• To devise a strategic plan for long-term future goals
Basic Science: Animal Biohazard
 Director: John Chan 
 Co-director: Larry Herbst
• To provide biosafety level 3 housing for mouse models of HIV
and opportunistic pathogens
• To supply HIV transgenic and SCID-hu mice
Basic Science: Clinical Virology
 Director: Harris Goldstein 
 Co-director: Tanya Dragic
• To contain a virus repository of clinical isolates and laboratory derived strains
• To analyze HIV specific RNA and DNA
• To prepare viral constructs or retroviral expression vectors
• To analyze HIV-specific immune responses
Immunology/Pathology
Director: Joan Berman 
 Director: Sunhee Lee
• To perform RNA and protein analysis as well as experimental
cellular immunology
• To perform histopathological analysis of tissue samples
Developmental
Director: Vinayaka Prasad
• To support collaborative and translational research by funding pilot projects
• To stimulate and support interactions among research at the AECOM/MMC
• To facilitate communication within the CFAR
Clinical Investigation
Director: Robert Klein
• To be a resource for clinical samples.
• To facilitate epidemiological studies of HIV in the Bronx and abroad
• To explore behavioral interventions to inhibit the spread of HIV
• To provide CFAR members with databases containing demographic, clinical
and research data related to individuals with or at risk for HIV infection
Basic Science: Flow Cytometry
Director: Stephen Porcelli
• To perform phenotypic analysis, tetramer analysis and flow
cytometric sorting of human or mouse cells
• To perform magnetic cell separation of cell populations
FUNCTIONS
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Table 1). The AECOM/MMC CFAR functions on multiple
levels to provide resources to HIV investigators and to
coordinate basic and clinical research projects. Its goals
are (1) to provide an institutional infrastructure to
facilitate collaborative research; (2) to establish and
maintain core facilities; (3) to provide scientific leader-
ship as well as intellectual and financial support for HIV
research; and (4) to educate the medical community as
well as the general population about HIV transmission,
prevention, and therapies. The AIDS research effort is
one of the major focuses of AECOM/MMC research
overall, with investigators receiving over 27 million
dollars/year of NIH funding for their individual HIV
research programs. Some trainees (postdoctoral fellows
and graduate students) are sponsored by other NIH-
funded programs, including the NIH AIDS Training
Program for Pre- and Postdoctoral Fellows, and the NIH
Experimental Neuropathology Training Grant. 
When the AECOM/MMC CFAR was newly funded, addi-
tional space was provided for Core Laboratories. There
are over 50 AECOM/MMC faculty participants in the
CFAR, many of whom use the specialized techniques
provided by the CFAR Core laboratories to support
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their research efforts. The investigators of the
AECOM/MMC CFAR are grouped into general programs
based on their research interests. These include the
studies of developmental therapeutics, epidemiology,
HIV-associated pathogens, immunology, substance
abuse and behavior, and viral pathogenesis. More
information about individual laboratories and Core
services can be found on the AECOM/MMC CFAR’s
homepage (http://www.aecom.yu.edu/home/cfar/). 
The CFAR promotes interactions among its investiga-
tors through the presentation of a bi-monthly AIDS
Club Seminar, where basic researchers and/or clinical
investigators who are members of the CFAR present
their latest findings to the AECOM/MMC communities.
The communication and interactions between clini-
cians and basic scientists has greatly improved. New
collaborations between physician scientists and basic
scientists have been initiated. For example, one project
is studying cytokine levels in HIV-infected patients, and
a second collaboration examines potential activation
markers in HIV-infected patients. In addition, the
AECOM/MMC CFAR held its first annual retreat in 2004
where members helped to educate one another about
the services provided by the individual Core laborato-
ries. One of the outcomes of the retreat was the devel-
opment of a mentorship program for junior clinical
investigators led by Dr. Julia Arnsten. Dr. Arnten organ-
izes monthly meetings that provide a forum where
junior clinicians can present their research proposals to
senior faculty, and they receive critical feedback before
submission of their formal proposals. 
The AECOM/MMC CFAR also fosters the research
careers of junior investigators by funding pilot projects
through the Developmental Core. In the past several
Investigator
Tanya Dragic, Ph.D. Small-molecule CCR5 antagonists
(i.e., SCH-351125/AD101)
Inhibition of HIV replication 
and viral entry
Tsamis et al., 2003 
Sunee Lee, M.D. Anti-HIV activity of the 
antibiotic minocycline
Inhibition of HIV replication 
at the transcriptional level
Si et al., 2004
Arturo Casadevall, M.D. 
Ekaterina Dadachova, M.D.
Fungal-binding monoclonal 
antibodies against Cryptococcus
neoformans
Conjugation of a radioactive
isotope to a fungal-specific 
antibody converts 
immunoglobulin into a
microbicidal molecule
Dadachova et al., 
2003
Joshua Nosanchuk, M.D. Voriconazole is fungicidal 
against Cryptococcus neoformans
High activity against both 
melanized and 
nonmelanized cells
van Duin et al., 2004 
William Jacobs, Jr., Ph.D. Novel vaccine strategies as 
prophylaxis for Micobacterium
tuberculosis
Double lysine and 
pantothenate auxotrophs 
are safe and effective
Sambandamurthy 
VK et al., 2005
Sambandamurthy 
and Jacobs, 2005
Robert Burk, M.D.
Mark Einstein, M.D.
Anna Kadish, M.D.
Vaccine strategies for 
management of Human
Papilloma Virus-induced neoplasia
Immunotherapy with 
vaccines offer both 
prevention and therapy 
for Human Papilloma Virus
Kadish and Einstein, 
2005 
Vinayaka Prasad, Ph.D. Small nucleic acid molecules 
isolated from combinatorial
libraries by systematic evolution 
of ligands by exponential 
enrichment (Aptamers)
Inhibition of HIV protein 
(i.e., reverse transcriptase) 
activity
Joshi and Prasad, 
2002 
Projects related to potential HIV therapeutics
Projects related to potential therapies for HIV-associated Pathogens
TABLE 2:  RESEARCH AT AECOM AIMED AT THERAPY FOR HIV AND RELATED PATHOGENS
Potential Therapeutic ReferenceDetails or Potential Mechanism
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years, the Developmental Core has funded more than
eleven pilot projects for junior investigators, ranging
from studies investigating HIV pathogenesis to studies
examining HIV transmission in developing nations.
BASIC SCIENCE RESEARCH AT THE ALBERT EINSTEIN
COLLEGE OF MEDICINE
Clinical HIV research was the main focus of the original
multi-institutional CFAR; however, the newly designed
AECOM/MMC CFAR targets translational research as
well as basic science. HIV is one of the best-studied
viruses, and recent research at AECOM has helped to
better our understanding of its life cycle at the molec-
ular level, with the hopes of finding some weakness
that can be exploited for therapy. Basic scientists are
exploring such topics as (1) the molecular interactions
between HIV proteins and host proteins (see the review
by Sorin and Kalpana, p. 10), (2) animal and cell culture
models of infection, (3) cytokine/chemokine produc-
tion and regulation, (4) virulence factors controlling co-
infectious pathogens, and (5) potential therapeutics
for HIV as a primary infection and its affiliated
secondary infections. A sampling of completed and
ongoing projects and their relation to potential thera-
peutics for HIV and related pathogens can be found in
Table 2, and some will be highlighted in the text below. 
Since HIV is specific to humans, it is difficult finding an
inexpensive animal model in which to test various
potential therapies. Dr. Goldstein’s laboratory has been
committed to outlining the blocks to HIV infection in
mice and has characterized various mouse models of HIV
infection. The blocks to HIV infection in mice occur at
various points in the viral life cycle, including the steps of
entry, transcription, and budding. One transgenic mouse
generated in Dr. Goldstein’s laboratory contains human-
derived receptors for HIV (Browning et al., 1997), and
another contains an intact HIV genome in the proviral
form incorporated into the murine DNA (Wang et al.,
2002). The latter mouse bypasses the need for the entry
and integration of HIV and can be used to analyze post-
integration phases of the life cycle. A third animal model
has proven useful for testing disseminated infection and
can potentially be used to screen new pharmacological
therapies (Pettoello-Mantovani et al., 1997). 
Despite the advances with Highly Active Antiretroviral
Therapy (HAART) for HIV-infected patients, the brain
remains the second most targeted organ, after the
lungs. Another area of interest at AECOM has been
central nervous system HIV pathology, which can clini-
cally manifest as HIV-associated dementia. Several
investigators characterized the natural history and
prevalence of HIV-associated dementia and the associ-
ated pathology, HIV encephalitis, including Drs. Dennis
Dickson, William Lyman and Karen Weidenheim (Kure
et al., 1989; Kure et al., 1990, Kure et al., 1991). They
established an in vitro system of HIV-infected microglial
cells that is an excellent model for HIV brain infection
(Lee et al., 1993). The model has become invaluable for
studying the neuroimmunological mechanisms that
contribute to HIV encephalitis. Activation of glial cells,
as studied by Dr. Sunhee C. Lee, indirectly contributes
to HIV encephalitis (see Lee and Dickson, 2005 for
review), but HIV and its component proteins can also
directly incite damage. Using the same type of culture
model developed by Dr. Dickson and colleagues, Dr.
Joan Berman’s laboratory is probing into the potential
neurotoxic effects of the HIV protein tat, and how the
toxicity can be modulated by endogenous chemokines
(Eugenin et al., 2003). 
In addition to research focusing directly on HIV, a
number of laboratories at AECOM investigate the
pathology and molecular biology of AIDS-associated
pathogens. For example, Drs. Arturo Casadevall,
Lisanne Pirofski, and Marta Feldmesser investigate the
virulence factors of and immune responses to the path-
ogenic fungi Cryptococcus neoformans and Aspergillus
fumigatus, which cause cryptococcosis and aspirgillosis,
respectively, in immunocompromised individuals. In
collaboration with Drs. Aharona Glatman-Freedman
and Ekaterina Datachova, Dr. Casadevall studies the
potential benefits of using protective monoclonal anti-
bodies to alter the outcome of diseases such as cypto-
coccosis and tuberculosis (TB). Dr. William Jacobs, Jr.
and colleagues also study Mycobacterium tuberculosis,
which, according to the World Health Organization
(WHO), caused 1.75 million deaths in 2003, and causes
13% of all AIDS deaths worldwide (WHO, 2005a). TB
has become a major problem in developing nations,
especially due to its drug resistance. Dr. Jacobs’ labora-
tory performs genetic analysis on M. tuberculosis in
order to study the genes that cause virulence and drug
resistance, and to identify new drug targets and
prepare novel vaccine formulations. 
Other researchers at AECOM study viral and protist
pathogens. Dr. Tanya Dragic, who has studied the struc-
ture of HIV glycoproteins that mediate viral entry, is
beginning to investigate the receptors that mediate
Hepatitis C virus entry. Drs. Anna Kadish, Robert Burk
and Mark Einstein study the pathogenesis of Human
papilloma virus-induced cervical cancer and are evalu-
ating a new vaccine as a prevention strategy. Protist
pathogens, including Toxoplasma gondii, microsporidia
and Plasmodium falciparum (which cause toxoplas-
mosis, microsporidiosis and malaria) are currently
being examined in multiple laboratories, including
those of Drs. Kami Kim and Louis Weiss. These exam-
ples of basic science research at AECOM have allowed
for a better understanding of the pathology and conse-
quences of HIV infection at molecular and cellular
levels, as well as at the level of the patient. Hopefully,
they will provide clues for adjunct therapies to treat
HIV and its confounding infections. 
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CLINICAL RESEARCH AT THE MONTEFIORE 
MEDICAL CENTER
In the days of the multi-institutional CFAR, clinical
researchers at MMC recruited a large number of HIV-
infected patients and they formed a large research
support system. Many clinicians at the MMC continue
study the substance abuse population of the Bronx,
including how substance abuse promotes HIV spread.
For example, Dr. Arnsten examines the relationship
between drug and alcohol use and non-adherence to
combination therapy (see Ramaswamy et al., p. 41 for
review and Howard et al., 2002), while Dr. Klein inves-
tigates the prevalence of opportunistic diseases in past
and present substance abusers. Furthermore, Dr.
Andrea Howard studies the abnormal glucose metabo-
lism in HIV-infected drug users (Howard et al., 2003).
Patients on HAART now have a chronic form of HIV and
they are living longer with the disease. Dr. Schoen-
baum’s interests lie with the natural history of
menopause in HIV-infected women (Miller et al., 2005),
and a companion study of hormone levels in HIV-
infected men is also being performed. Behavioral inter-
ventions are currently being investigated in a number
of distinct projects. Dr. Laure Bauman heads “Primary
Care,” which involves custody planning intervention for
children of AIDS-afflicted mothers (Silver et al., 2003).
She also examines the extent to which children are
caring for their HIV-infected parents. Furthermore, she
targets Bronx adolescents aged 14-17 in “Generation
Safe,” an HIV, drug and alcohol prevention program. 
GOING BEYOND THE BRONX: INTERNATIONAL
RESEARCH AND OUTREACH EFFORTS
While there is no cure for HIV/AIDS, it is highly treat-
able with combination therapy in the developed world,
where countries are affluent and have access to costly
antiretroviral medications. Many low- and middle-
income nations are poverty-stricken and do not have
the resources to control the spread of HIV effectively
(see Harris et al. for review, p. 25). The prevalence of
HIV in developing nations is estimated by the Joint
United Nations Programme on HIV/AIDS (UNAIDS) and
the WHO (see www.UNAIDS .org and www.WHO.org
for more information). A number of United Nations-
funded programs have been initiated, most notably the
“3 by 5” target program, whose goals are to treat three
million HIV-infected people in low- and middle-income
countries with antiretroviral drugs by the end of 2005.
WHO estimates that only 970,000 HIV-infected people
of the six and a half million who need antiretroviral
therapy in low- and middle-income countries had access
to the drugs by June 2005 (WHO, 2005b). Although the
“3 by 5” program might be falling short of its target
goal, the number of people receiving therapy has
steadily increased in the past year. For example, the
number of people receiving therapy has tripled in Sub-
Saharan Africa, reaching 500,000 (WHO, 2005b).
Nations in Africa would benefit from additional finan-
cial support, but aid groups were unhappy about the
proposed pledges from the world’s economic leaders at
this year’s G8 summit, stating that Africa has been
“shortchanged.” (Associated Press, 2005). 
Despite all of the obstacles, researchers from
AECOM/MMC are doing their part to study HIV in
developing nations and are even trying to help relieve
some of the burden of getting antiretroviral drugs to
the places that need it most. Dr. Nina Cooperman has
studied the effects of HIV on women in NYC (Coop-
erman and Simoni, 2005) and she has extended her
work to Mumbai, India, where she plans to examine
HIV in sex workers and housewives. The NIH also
supports an international training program (directed
by Dr. Vinayaka Prasad) centering on AIDS and tuber-
culosis prevention research. The goals of this training
grant are to supply Indian and Eritrean scientists with a
place to perform biomedical and clinical research,
including behavioral and epidemiological studies. In
India, HIV-1 subtype C is more prevalent than subtype B
forms typical of Western countries. In collaboration
with Dr. William Tyor at the Medical University of South
Carolina, Dr. Prasad is studying the molecular charac-
teristics of HIV that may control the difference in the
prevalence of HIV-associated dementia between
subtype C and subtype B. They are using the mouse
model of HIV encephalitis described in this issue (see
the article by Cook and Tyor, p. 32). Moreover,
AECOM/MMC researchers are also working in South
America. One study described in this issue was
performed by Samayoa et al. (p. 49) and involved the
potential risk to health care workers of contracting HIV
from potentially infectious substances in Guatemala. 
Africa is by far the most severely affected continent in
terms of the HIV pandemic and several AECOM/MMC
researchers are conducting research in various regions
of Africa. In this issue, Langman et al. (p. 53) discuss
their work performed in Kumba, Cameroon. In affilia-
tion with Dr. Ernest Drucker of the MMC and Dr.
Preston Marx of Tulane University, Dr. Yaron Langman
investigated the contribution of blood transfusions to
the HIV epidemic. Furthermore, Dr. Donna Futterman
has initiated a program in South Africa for the preven-
tion of vertical transmission of HIV. Additionally, Dr.
Carol Harris established the Global Institute of HIV
Medicine in 2001. The goals of the institute are (1) to
teach state-of-the-art HIV medicine; (2) to understand
and describe the cultural, economic and political
barriers impeding the implementation of frontline
programs; and (3) to act as a force for advice and
change, and to enhance initiatives for the prevention
and treatment of AIDS (Harris, 2005a). Dr. Harris has a
pilot grant from the AECOM/MMC CFAR to determine
the response to antiretroviral therapy in the Democ-
ratic Republic of Ethiopia. Dr. Harris also plays an
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important role in training physicians locally and
abroad. When she became aware of the dearth in
knowledge regarding HIV management that existed on
the home front, she established “HIV Management–the
New York Course,” in collaboration with Dr. Klein and
Mindy Cimino (HIV Management, 2005). This course
conveys up-to-date comprehensive HIV management
information for New York physicians. Dr. Harris assists
in training physicians around the world about HIV
management through the Global AIDS Learning and
Evaluation Network, whose modules have been used in
Africa, the Caribbean, Eastern Europe, and China
(Harris, 2005b).
CONCLUSION
The CFAR of the AECOM/MMC has fostered HIV/AIDS
research for almost 20 years and it is currently going
strong. The projects it funds are clinical, basic science,
and translational in nature. HAART has drastically
altered the course of HIV infection in patients and
AECOM/MMC clinicians continue to study it in the
Bronx population. In addition, basic scientists explore
the intricacies of the HIV life cycle so that we may have
a better understanding of how to manipulate it to our
advantage. The CFAR’s support is playing an important
role in coordinating HIV research within the
AECOM/MMC and abroad. With their knowledge,
investigators have branched out to fight the HIV
pandemic across several continents; and, with their
research, they may one day find a novel therapy or a
vaccine for one of history’s most devastating diseases. 
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